Gene Silencing in Cancer in Association with Promoter Hypermethylation
The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Abstract
This article reviews the mechanisms of gene silencing in cancer and clinical applications of this phenomenon. The silencing of genes, especially tumor-suppressor genes, is a key event in the development of cancer. The silencing can be effected by a disabling mutation or by a shutting down of the promoter region, the site at which transcription of the gene begins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
Okano, M., Bell, D. W., Haber, D. A., & Li, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81656-6 · Cited by 6,143
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Self-citationMethylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Self-citationTargeted mutation of the DNA methyltransferase gene results in embryonic lethality
Li, E., Bestor, T. H., & Jaenisch, R. (1992) · Cell · doi:10.1016/0092-8674(92)90611-f · Cited by 3,984
Hypomethylation distinguishes genes of some human cancers from their normal counterparts
Feinberg, A. P., & Vogelstein, B. (1983) · Nature · doi:10.1038/301089a0 · Cited by 2,437
Cancer-epigenetics comes of age
Jones, P. A., & Laird, P. W. (1999) · Nature Genetics · doi:10.1038/5947 · Cited by 2,344
Cited by
Items 101–200 of 207
Leukaemogenesis: more than mutant genes
Chen, J., Odenike, O., & Rowley, J. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2765 · Cited by 311
Epigenetic control of female puberty
Lomniczi, A., Loche, A., Castellano, J. M., Ronnekleiv, O. K., Bosch, M., Kaidar, G., Knoll, J. G., Wright, H., Pfeifer, G. P., & Ojeda, S. R. (2013) · Nature Neuroscience · doi:10.1038/nn.3319 · Cited by 309
Estrogen Receptor β: An Overview and Update
Zhao, C., Dahlman-Wright, K., & Gustafsson, J.-Å. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06003 · Cited by 309
Devlin, A. M., Brain, U., Austin, J., & Oberlander, T. F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012201 · Cited by 308
“Epigenetic processes include DNA methylation and chromatin modifications (histone methylation, acetylation), patterns of which are inherited [4,5] but are responsive to environmental shifts, such as stress, and are especially vulnerable during development [6–8].”
BackgroundEpigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
Koch, A., Jeschke, J., Van Criekinge, W., van Engeland, M., & De Meyer, T. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz445 · Cited by 306
DNA methylation markers in colorectal cancer
Kim, M. S., Lee, J., & Sidransky, D. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9207-6 · Cited by 303
Microsatellite instability in colorectal cancer
Söreide, K., Janssen, E. A. M., Söiland, H., Körner, H., & Baak, J. P. A. (2006) · British Journal of Surgery · doi:10.1002/bjs.5328 · Cited by 302
Agirre, X., Vilas-Zornoza, A., Jiménez-Velasco, A., Martin-Subero, J. I., Cordeu, L., Gárate, L., San José-Eneriz, E., Abizanda, G., Rodríguez-Otero, P., Fortes, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4025 · Cited by 302
DNA Methylation as a Therapeutic Target in Cancer
Issa, J.-P. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2076 · Cited by 301
Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment
Li, L.-C., Carroll, P. R., & Dahiya, R. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji010 · Cited by 299
Veeriah, S., Brennan, C., Meng, S., Singh, B., Fagin, J. A., Solit, D. B., Paty, P. B., Rohle, D., Vivanco, I., Chmielecki, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900571106 · Cited by 299
Cancer epigenetics: linking basic biology to clinical medicine
Tsai, H.-C., & Baylin, S. B. (2011) · Cell Research · doi:10.1038/cr.2011.24 · Cited by 297
Self-citationMicroRNA signatures of TRAIL resistance in human non-small cell lung cancer
Garofalo, M., Quintavalle, C., Di Leva, G., Zanca, C., Romano, G., Taccioli, C., Liu, C. G., Croce, C. M., & Condorelli, G. (2008) · Oncogene · doi:10.1038/onc.2008.6 · Cited by 289
Issa, J.-P. J., Gharibyan, V., Cortes, J., Jelinek, J., Morris, G., Verstovsek, S., Talpaz, M., Garcia-Manero, G., & Kantarjian, H. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.981 · Cited by 288
Epigenetic Mechanisms in Inflammation
Bayarsaihan, D. (2011) · Journal of Dental Research · doi:10.1177/0022034510378683 · Cited by 287
McGarvey, K. M., Fahrner, J. A., Greene, E., Martens, J., Jenuwein, T., & Baylin, S. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2481 · Cited by 286
Self-citationLi, Y., Ge, D., & Lu, C. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0316-3 · Cited by 285
The Ras-association domain family (RASSF) members and their role in human tumourigenesis
van der Weyden, L., & Adams, D. J. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.06.003 · Cited by 284
Wu, Y., Halverson, G., Basir, Z., Strawn, E., Yan, P., & Guo, S.-W. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.01.034 · Cited by 283
Kew, M. C. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06546.x · Cited by 279
A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer
Sandoval, J., Mendez-Gonzalez, J., Nadal, E., Chen, G., Carmona, F. J., Sayols, S., Moran, S., Heyn, H., Vizoso, M., Gomez, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5516 · Cited by 278
Loss of 5‐hydroxymethylcytosine is accompanied with malignant cellular transformation
Kudo, Y., Tateishi, K., Yamamoto, K., Yamamoto, S., Asaoka, Y., Ijichi, H., Nagae, G., Yoshida, H., Aburatani, H., & Koike, K. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02213.x · Cited by 278
Aryee, M. J., Liu, W., Engelmann, J. C., Nuhn, P., Gurel, M., Haffner, M. C., Esopi, D., Irizarry, R. A., Getzenberg, R. H., Nelson, W. G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005211 · Cited by 275
Linhart, H. G., Lin, H., Yamada, Y., Moran, E., Steine, E. J., Gokhale, S., Lo, G., Cantu, E., Ehrich, M., He, T., et al. (2007) · Genes & Development · doi:10.1101/gad.1594007 · Cited by 274
Wnt Inhibitory Factor-1 Is Silenced by Promoter Hypermethylation in Human Lung Cancer
Mazieres, J., He, B., You, L., Xu, Z., Lee, A. Y., Mikami, I., Reguart, N., Rosell, R., McCormick, F., & Jablons, D. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1389 · Cited by 271
Human embryonic stem cells have a unique epigenetic signature
Bibikova, M., Chudin, E., Wu, B., Zhou, L., Garcia, E. W., Liu, Y., Shin, S., Plaia, T. W., Auerbach, J. M., Arking, D. E., et al. (2006) · Genome Research · doi:10.1101/gr.5319906 · Cited by 271
Caloric restriction delays age-related methylation drift
Maegawa, S., Lu, Y., Tahara, T., Lee, J. T., Madzo, J., Liang, S., Jelinek, J., Colman, R. J., & Issa, J.-P. J. (2017) · Nature Communications · doi:10.1038/s41467-017-00607-3 · Cited by 270
Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1104 · Cited by 270
Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis
Fang, F., Turcan, S., Rimner, A., Kaufman, A., Giri, D., Morris, L. G. T., Shen, R., Seshan, V., Mo, Q., Heguy, A., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001875 · Cited by 267
Self-citationDNA Methylation Changes after 5-Aza-2′-Deoxycytidine Therapy in Patients with Leukemia
Yang, A. S., Doshi, K. D., Choi, S.-W., Mason, J. B., Mannari, R. K., Gharybian, V., Luna, R., Rashid, A., Shen, L., Estecio, M. R. H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2385 · Cited by 266
Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer
Leão, R., Apolónio, J. D., Lee, D., Figueiredo, A., Tabori, U., & Castelo-Branco, P. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0422-8 · Cited by 265
Kim, Y.-I. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.11.2703 · Cited by 265
Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer
Agrelo, R., Cheng, W.-H., Setien, F., Ropero, S., Espada, J., Fraga, M. F., Herranz, M., Paz, M. F., Sanchez-Cespedes, M., Artiga, M. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600645103 · Cited by 264
Zhang, Q., Wang, H. Y., Marzec, M., Raghunath, P. N., Nagasawa, T., & Wasik, M. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501959102 · Cited by 262
Paz, M. F., Yaya-Tur, R., Rojas-Marcos, I., Reynes, G., Pollan, M., Aguirre-Cruz, L., García-Lopez, J. L., Piquer, J., Safont, M.-J., Balaña, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0392 · Cited by 261
The role of DNA methylation in cancer development.
Łuczak, M. W., & Jagodziński, P. P. (2006) · PubMed · doi:10.5603/4561 · Cited by 260
Schulmann, K., Sterian, A., Berki, A., Yin, J., Sato, F., Xu, Y., Olaru, A., Wang, S., Mori, Y., Deacu, E., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208598 · Cited by 259
Curcumin use in pulmonary diseases: State of the art and future perspectives
Lelli, D., Sahebkar, A., Johnston, T. P., & Pedone, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.017 · Cited by 258
Epigenetics: Connecting Environment and Genotype to Phenotype and Disease
Barros, S. P., & Offenbacher, S. (2009) · Journal of Dental Research · doi:10.1177/0022034509335868 · Cited by 258
Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma
D'souza, S., Lau, K. C., Coffin, C. S., & Patel, T. R. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i38.5759 · Cited by 257
So, J. Y., Ohm, J., Lipkowitz, S., & Yang, L. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108253 · Cited by 256
Kuendgen, A., Strupp, C., Aivado, M., Bernhardt, A., Hildebrandt, B., Haas, R., Germing, U., & Gattermann, N. (2004) · Blood · doi:10.1182/blood-2003-12-4333 · Cited by 255
Veeck, J., Niederacher, D., An, H., Klopocki, E., Wiesmann, F., Betz, B., Galm, O., Camara, O., Dürst, M., Kristiansen, G., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209386 · Cited by 254
Epigenetic Inactivation of the miR-124-1 in Haematological Malignancies
Wong, K. Y., So, C. C., Loong, F., Chung, L. P., Lam, W. W. L., Liang, R., Li, G. K. H., Jin, D.-Y., & Chim, C. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019027 · Cited by 247
“transferase [1,2].”
Histone acetylation in gene regulation
Verdone, L. (2006) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/ell028 · Cited by 244
“The loss of DNA methylation at CpG dinucleotides in cancer cells was reported [97], and since this observation, the relations between cancer and DNA methylation were thoroughly studied [98–101].”
BackgroundEpigenetics and environment: a complex relationship
Aguilera, O., Fernández, A. F., Muñoz, A., & Fraga, M. F. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00068.2010 · Cited by 241
“These dinucleotide sites are usually referred to as CpGs (41).”
BackgroundShah, M. H., Binkley, P., Chan, K., Xiao, J., Arbogast, D., Collamore, M., Farra, Y., Young, D., & Grever, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2689 · Cited by 241
“In recent years, the importance of epigenetic modification in the initiation and progression of human cancer has risen to the forefront (1).”
Backgroundp53 and Nur77/TR3 – transcription factors that directly target mitochondria for cell death induction
Moll, U. M., Marchenko, N., & Zhang, X.-K. (2006) · Oncogene · doi:10.1038/sj.onc.1209601 · Cited by 240
“However, many human cancers have lost this prerequisite due to global epigenetic deregulation of their genome, leading to broadly aberrant gene silencing patterns (Herman and Baylin, 2003).”
BackgroundCancer epigenetics in clinical practice
Davalos, V., & Esteller, M. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21765 · Cited by 237
“Using primers designed to distinguish methylated from unmethylated CpGs in bisulfite‐modified DNA, methylation‐specific polymerase chain reaction (PCR)(19) was a pivotal method to establish the relevance of promoter‐associated CpG island hypermethylation in cancer and to identify potential biomarkers of clinical utili…”
MethodGlöckner, S. C., Dhir, M., Yi, J. M., McGarvey, K. E., Van Neste, L., Louwagie, J., Chan, T. A., Kleeberger, W., de Bruïne, A. P., Smits, K. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0142 · Cited by 230
Self-citationThe fundamental role of epigenetics in hematopoietic malignancies
Galm, O., Herman, J. G., & Baylin, S. B. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.01.006 · Cited by 230
Self-citationEvolution of decitabine development: Accomplishments, ongoing investigations, and future strategies
Jabbour, E., Issa, J., Garcia‐Manero, G., & Kantarjian, H. (2008) · Cancer · doi:10.1002/cncr.23463 · Cited by 224
“silencing is exploited by cancers to fully express the malignant phenotype.(3) Evidence supporting a role of epigenetic gene silencing in tumorigenesis stems from studies revealing a large number of genes that are silenced by aberrant DNA methylation in different types of cancers, many of which are involved in the con…”
BackgroundEpigenetic reprogramming of cancer cells via targeted DNA methylation
Rivenbark, A. G., Stolzenburg, S., Beltran, A. S., Yuan, X., Rots, M. G., Strahl, B. D., & Blancafort, P. (2012) · Epigenetics · doi:10.4161/epi.19507 · Cited by 223
“Neoplastic transformation is associated with alterations in DNA methylation, including both global hypomethylation and gene-specific hypermethylation.(7) Gains in DNA methylation in cancer cells typically reflect hypermethylation of CpG islands in gene promoter regions, which can lead to gene silencing.”
BackgroundDNA methylation in glioblastoma: impact on gene expression and clinical outcome
Etcheverry, A., Aubry, M., de Tayrac, M., Vauleon, E., Boniface, R., Guenot, F., Saikali, S., Hamlat, A., Riffaud, L., Menei, P., et al. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-701 · Cited by 223
“The role of general epigenetic mechanisms in carcinogenesis and tumor aggressiveness is well documented: CpG island hypermethylation silences tumor suppressor genes, whereas hypomethylation promotes the transcriptional activation of oncogenes and induces chromosomal instability [4,5].”
BackgroundEpigenetic Regulation of Cancer Stem Cell Marker Cd133 by Transforming Growth Factor-β
You, H., Ding, W., & Rountree, B. C. (2010) · Hepatology · doi:10.1002/hep.23544 · Cited by 221
“CpG hypermethylation in promoter regions of tumor suppressors has been linked to tumorigenesis.(21,22) For example, Ras and downstream Ras effectors were activated due to epigenetic silencing of inhibitors of the Ras pathway in HCC.”
BackgroundSustained IL-6/STAT-3 Signaling in Cholangiocarcinoma Cells Due to SOCS-3 Epigenetic Silencing
Isomoto, H., Mott, J. L., Kobayashi, S., Werneburg, N. W., Bronk, S. F., Haan, S., & Gores, G. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.10.037 · Cited by 219
“Although DAC has been shown to sensitize cells to apoptosis by multiple mechanisms,34, 53–55 we did not observe a significant change in other apoptosis modulators in our current study.”
BackgroundDifferences between human embryonic stem cell lines
Allegrucci, C., & Young, L. E. (2007) · Human Reproduction Update · doi:10.1093/humupd/dml041 · Cited by 217
“DNA methylation alteration at non-imprinted genomic loci can induce genomic instability and is associated with cancer (Gaudet et al., 2003; Herman and Baylin, 2003; Baylin, 2005; Esteller, 2005).”
Regulation of Tumor Progression by Programmed Necrosis
Lee, S. Y., Ju, M. K., Jeon, H. M., Jeong, E. K., Lee, Y. J., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3537471 · Cited by 215
“In addition, these changes lead to genetic limitations in apoptotic pathways, which enhances necrotic cell death [9, 227].”
BackgroundZinn, R. L., Pruitt, K., Eguchi, S., Baylin, S. B., & Herman, J. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3396 · Cited by 210
Self-citationEpigenetics in cancer therapy and nanomedicine
Roberti, A., Valdes, A. F., Torrecillas, R., Fraga, M. F., & Fernandez, A. F. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0675-4 · Cited by 205
Clinical use of circulating nucleosomes
Holdenrieder, S., & Stieber, P. (2009) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360802485875 · Cited by 200
The tumor suppressor RASSF1A in human carcinogenesis: an update.
Dammann, R., Schagdarsurengin, U., Seidel, C., Strunnikova, M., Rastetter, M., Baier, K., & Pfeifer, G. P. (2005) · PubMed · doi:10.14670/hh-20.645 · Cited by 197
Donson, A. M., Addo‐Yobo, S. O., Handler, M. H., Gore, L., & Foreman, N. K. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.20803 · Cited by 196
“In the course of tumor development, gene silencing by DNA methylation is an early and important mechanism by which oncogenes or tumor suppressors can be inactivated [19].”
BackgroundModification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A.
Milhem, M., Mahmud, N., Lavelle, D., Araki, H., DeSimone, J., Saunthararajah, Y., & Hoffman, R. (2004) · Blood · doi:10.1182/blood-2003-07-2431 · Cited by 195
Boyanapalli, S. S. S., & Kong, A. N. T. (2015) · Current Pharmacology Reports · doi:10.1007/s40495-015-0018-x · Cited by 195
Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth
Lin, J., Haffner, M. C., Zhang, Y., Lee, B. H., Brennen, W. N., Britton, J., Kachhap, S. K., Shim, J. S., Liu, J. O., Nelson, W. G., et al. (2011) · The Prostate · doi:10.1002/pros.21247 · Cited by 194
“Methylation of CpG dinucleotides in gene promoter regions can result in silencing of gene expression [7–9].”
BackgroundPerri, F., Cotugno, R., Piepoli, A., Merla, A., Quitadamo, M., Gentile, A., Pilotto, A., Annese, V., & Andriulli, A. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01284.x · Cited by 194
“59 ≥200 g × 3/wk 24 (53) 10 (22) 6 (13) 1 (2) 4 (9) Vegetables (%) <200 g × 5/wk 2 (67) 1.”
BackgroundDLC‐1:a Rho GTPase‐activating protein and tumour suppressor
Durkin, M. E., Yuan, B., Zhou, X., Zimonjic, D. B., Lowy, D. R., Thorgeirsson, S. S., & Popescu, N. C. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00098.x · Cited by 191
“Epigenetic mechanisms also lead to silencing of tumour suppressor genes, and hypermethylation of cytosine bases within CpG dinucleotides in GC-rich promoter regions is the best characterized chromatin modification associated with transcriptional repression in human malignancies [93].”
BackgroundRighini, C. A., de Fraipont, F., Timsit, J.-F., Faure, C., Brambilla, E., Reyt, E., & Favrot, M.-C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2027 · Cited by 190
Nabel, C. S., Manning, S. A., & Kohli, R. M. (2012) · ACS Chemical Biology · doi:10.1021/cb2002895 · Cited by 189
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
Metzeler, K. H., Walker, A., Geyer, S., Garzon, R., Klisovic, R. B., Bloomfield, C. D., Blum, W., & Marcucci, G. (2012) · Leukemia · doi:10.1038/leu.2011.342 · Cited by 186
Peng, D. F., Razvi, M., Chen, H., Washington, K., Roessner, A., Schneider-Stock, R., & El-Rifai, W. (2009) · Gut · doi:10.1136/gut.2007.146290 · Cited by 185
Jeuken, J. W. M., Cornelissen, S. J. B., Vriezen, M., Dekkers, M. M. G., Errami, A., Sijben, A., Boots-Sprenger, S. H. E., & Wesseling, P. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700664 · Cited by 180
“For example, it has been shown that aberrant promoter hypermethylation of one allele with mutation or loss of heterozygosity in the other allele, or methylation of both alleles, has the same effect, that is, functional inactivation of the gene.(31,32) Interestingly, MGMT hypermethylation is detected in part of the GBM…”
BackgroundLoss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer
Chen, K., Zhang, J., Guo, Z., Ma, Q., Xu, Z., Zhou, Y., Xu, Z., Li, Z., Liu, Y., Ye, X., et al. (2016) · Cell Research · doi:10.1038/cr.2015.150 · Cited by 174
Definition, conservation and epigenetics of housekeeping and tissue-enriched genes
She, X., Rohl, C. A., Castle, J. C., Kulkarni, A. V., Johnson, J. M., & Chen, R. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-269 · Cited by 173
“Chromatin structure and epigenetic modifications of genomic structure have been documented to regulate gene expression and affect replication, recombination and DNA repair [6,7] through various mechanisms including nucleosome positioning and occupancy, histone modification (mainly acetylation and methylation) and DNA…”
Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions
Adiwidjaja, J., McLachlan, A. J., & Boddy, A. V. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1360279 · Cited by 173
“Hypermethylation of regulatory CpG islands in tumor suppressor genes could promote proliferation of tumor cells [41].”
BackgroundEpigenetic aberrations during oncogenesis
Hatziapostolou, M., & Iliopoulos, D. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0624-z · Cited by 169
“Key tumor suppressor proteins, such as the cell cycle inhibitor p16INK4a, the p-53 regulator p14ARF, the cell adherence protein E-cadherin, or the estrogen and retinoid receptors, were shown to undergo methylation-associated silencing in cancer cell lines and primary tumors [28, 30].”
BackgroundResistance to Chemotherapy in Cancer: A Complex and Integrated Cellular Response
Mellor, H. R., & Callaghan, R. (2008) · Pharmacology · doi:10.1159/000115967 · Cited by 168
Kuang, S.-Q., Tong, W.-G., Yang, H., Lin, W., Lee, M. K., Fang, Z. H., Wei, Y., Jelinek, J., Issa, J.-P., & Garcia-Manero, G. (2008) · Leukemia · doi:10.1038/leu.2008.130 · Cited by 165
Epigenetics: poly(ADP‐ribosyl)ation of PARP‐1 regulates genomic methylation patterns
Caiafa, P., Guastafierro, T., & Zampieri, M. (2009) · The FASEB Journal · doi:10.1096/fj.08-123265 · Cited by 165
“(28); in contrast, chromatin decondensation (29),”
The MicroRNA-148/152 Family: Multi-faceted Players
Chen, Y., Song, Y.-X., & Wang, Z.-N. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-43 · Cited by 164
“Based on these two studies, we hypothesize that methylation of CpG islands in miR-148/152 family member genes might induce particular biological behaviors of cancer.”
InfluentialBraiteh, F., Soriano, A. O., Garcia-Manero, G., Hong, D., Johnson, M. M., Silva, L. D. P., Yang, H., Alexander, S., Wolff, J., & Kurzrock, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1247 · Cited by 164
“abundantly located in and near specific gene promoters and in DNA-repetitive elements such as long interspersed nucleotide elements (4).”
BackgroundJuo, Y. Y., Johnston, F. M., Zhang, D. Y., Juo, H. H., Wang, H., Pappou, E. P., Yu, T., Easwaran, H., Baylin, S., van Engeland, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu149 · Cited by 164
“Aberrant methylation of cytosine nucleotides within these CpG islands can lead to aberrant silencing of normal tumor-suppressor function and cancer formation [1, 2].”
BackgroundSelf-citationDNA methylation biomarkers in cancer: progress towards clinical implementation
Mikeska, T., Bock, C., Do, H., & Dobrovic, A. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.45 · Cited by 161
Russo, A. L., Thiagalingam, A., Pan, H., Califano, J., Cheng, K.-H., Ponte, J. F., Chinnappan, D., Nemani, P., Sidransky, D., & Thiagalingam, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1962 · Cited by 145
Dynamic DNA methylation during aging: A "prophet" of age-related outcomes
Xiao, F.-H., Wang, H.-T., & Kong, Q.-P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00107 · Cited by 140
Epigenetic regulation of female puberty
Lomniczi, A., Wright, H., & Ojeda, S. R. (2015) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.08.003 · Cited by 136
“, those heritable changes in gene expression that occur without changing the primary nucleotide sequence of a gene (Wolffe and Matzke, 1999; Herman and Baylin, 2003).”
BackgroundElevated levels of DNA methylation at the OPRM1 promoter in blood and sperm from male opioid addicts
Chorbov, P., Todorov, P., Lynskey, P., & Cicero, P. (2018) · Journal of Opioid Management · doi:10.5055/jom.2011.0067 · Cited by 135
Raffoux, E., Cras, A., Recher, C., Boëlle, P.-Y., de Labarthe, A., Turlure, P., Marolleau, J.-P., Reman, O., Gardin, C., Victor, M., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.106 · Cited by 134
“Chromatine remodeling through DNA demethylation has been investigated for many years as a potential anticancer therapeutic approach [1].”
BackgroundWnt/β-catenin signalling in adrenal physiology and tumour development
Berthon, A., Martinez, A., Bertherat, J., & Val, P. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.009 · Cited by 125
The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia
Agrawal, S., Hofmann, W.-K., Tidow, N., Ehrich, M., Boom, D. V. D., Koschmieder, S., Berdel, W. E., Serve, H., & Müller-Tidow, C. (2007) · Blood · doi:10.1182/blood-2006-08-040147 · Cited by 119
Epigenetics as a Therapeutic Target in Breast Cancer
Connolly, R., & Stearns, V. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9263-3 · Cited by 117
DNA methylation in endometriosis (Review)
KOUKOURA, O., SIFAKIS, S., & SPANDIDOS, D. A. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4925 · Cited by 103
“majority of CpG islands in gene promoters are unmethylated, which allows active gene transcription (32,35).”
BackgroundEvans, D. G. R., van Veen, E. M., Byers, H. J., Wallace, A. J., Ellingford, J. M., Beaman, G., Santoyo-Lopez, J., Aitman, T. J., Eccles, D. M., Lalloo, F. I., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.07.002 · Cited by 95
Li, X., Peterson, Y. K., Inks, E. S., Himes, R. A., Li, J., Zhang, Y., Kong, X., & Chou, C. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00136 · Cited by 93
HIC1 attenuates Wnt signaling by recruitment of TCF‐4 and β‐catenin to the nuclear bodies
Valenta, T., Lukas, J., Doubravska, L., Fafilek, B., & Korinek, V. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601147 · Cited by 91
“tumors (Herman and Baylin, 2003).”
BackgroundDigging deep into “dirty” drugs – modulation of the methylation machinery
Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84
“Keywords Acute myeloid leukemia, azacitidine, decitabine, DNA methylation, epigenetics, hypomethylating agents, myelodysplastic syndrome, transcriptional regulation History Received 12 October 2014 Revised 26 November 2014 Accepted 1 December 2014 Published online 8 January 2015”
BackgroundDNA Methylation, Genomic Silencing, and Links to Nutrition and Cancer
McCabe, D. C., & Caudill, M. A. (2005) · Nutrition Reviews · doi:10.1111/j.1753-4887.2005.tb00136.x · Cited by 78
Frequent epigenetic silencing of PCDH10 by methylation in human colorectal cancer
Zhong, X., Zhu, Y., Mao, J., Zhang, J., & Zheng, S. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1353-5 · Cited by 76
Metadata
- Authors
- Herman, J. G., & Baylin, S. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-11-20
- Volume
- 349
- Issue
- 21
- Pages
- 2042-2054
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2040257851
- Cited by
- 3,422
- References
- 130
- FWCI
- 46.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.